The most common reason for plasma transfusion is the correction of an elevated international normalized ratio (INR) despite a lack of evidence to support such a practice. 3, 4 In the United Kingdom, more than 10% of patients admitted to the intensive care unit (ICU) receive plasma with the majority of transfusions occurring in the absence of active bleeding. 5 Moreover, nearly 80% of plasma administered to nonbleeding patients occurs at mild-to-moderate levels of INR elevation (ie, INR ≤ 2.5). Although plasma administration may lead to a fall in markedly elevated INRs, there is only a modest associated rise in actual coagulation factor levels due in large part to the nonlinear relationship between factor levels and INR. 3, 6, 7 In addition, plasma does not reliably correct mild-to-moderate elevations in INR or induce a more procoagulant state. 5, [8] [9] [10] Perhaps most importantly, the assumption that mild-to-moderate elevations of INR confer increased bleeding risk lacks the support of robust experimental evidence. 3, 11, 12 Notably, plasma transfusion is not without risk. Specifically in the critically ill population, plasma administration has been associated with a myriad of complications, including transfusion-related acute lung injury, 1, [13] [14] [15] [16] circulatory overload, 17, 18 multiorgan failure, 15, 19 and infectious complications. 20 Therefore, it is essential that any discussion of presumed benefits of transfusion therapies be balanced with thorough assessment of patient risk.
Given the uncertainty surrounding the efficacy of plasma transfusion for nonbleeding ICU patients, the aim of this investigation was to assess the relationships between prophylactic plasma administration and bleeding complications, with a primary outcome of red blood cell (RBC) transfusion. We hypothesized that prophylactic plasma BACKGROUND: Critically ill patients frequently receive plasma transfusion under the assumptions that abnormal coagulation test results confer increased risk of bleeding and that plasma transfusion will decrease this risk. However, the effect of prophylactic plasma transfusion remains poorly understood. The objective of this study was to determine the relationship between prophylactic plasma transfusion and bleeding complications in critically ill patients. METHODS: This is a retrospective cohort study of adults admitted to the intensive care unit (ICU) at a single academic institution between January 1, 2009 and December 31, 2013. Inclusion criteria included age ≥18 years and an international normalized ratio measured during ICU admission. Multivariable propensity-matched analyses were used to evaluate associations between prophylactic plasma transfusion and outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of hospital-and ICU-free days and mortality within 30 days of ICU discharge. RESULTS: A total of 27,561 patients were included in the investigation with 2472 (9.0%) receiving plasma therapy and 1105 (44.7%) for which plasma transfusion was prophylactic in nature. In multivariable propensity-matched analyses, patients receiving plasma had higher rates of red blood cell transfusion (odds ratio: 4.3 [95% confidence interval: 3.3-5.7], P < .001) and fewer hospital-free days (estimated % increase: −11.0% [95% confidence interval: −11.4, −10.6%], P < .001). There were no significant differences in ICU-free days or mortality. These findings appeared robust, persisting in multiple predefined sensitivity analyses. 
METHODS
This is a retrospective cohort study conducted under the approval of the Mayo Clinic (Rochester, Minnesota) Institutional Review Board with a waived requirement for written informed consent. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used in the design and conduct of the study. 21 The study population includes adult patients admitted to 2 medical, 3 surgical, and 1 combined medical-surgical ICU at a tertiary care academic medical center. Basic ICU characteristics are provided in Supplemental The primary exposure variable for this investigation was the presence or absence of prophylactic plasma transfusion within 24 hours of the qualifying INR value. Prophylactic plasma transfusion was defined as the first episode of plasma administration during the qualifying ICU admission, excluding those patients that had received RBC transfusion in the 24 hours before INR measurement or plasma administration. The presence and timing of all transfusion episodes were extracted from the electronic health record, with the timing of transfusion defined as the actual transfusion initiation time rather than the time of component issue from the blood bank.
The primary outcome for this investigation was RBC transfusion within 24 hours of the qualifying INR value for nonplasma-transfused patients and within 24 hours of plasma transfusion for plasma-transfused patients. Secondary outcome measures included ICU-and hospital-free days (defined as 28 minus the ICU or hospital length of stay in days, with patients dying before discharge and those with ICU or hospital durations greater than 28 days receiving a score of 0), and all-cause mortality within 30 days of ICU discharge.
Relevant information for study participants was extracted using the Perioperative Datamart, an institutional resource that contains clinical, demographic, transfusion, and laboratory data for patients admitted to acute care environments. 22 Additional baseline characteristics were obtained from the Mayo Clinic Life Sciences System (MCLSS), a second institutional database. 23 Extensive validation has been performed on these databases, and the accuracy of extracted data is superior to that collected by manual methods. 24 
Statistical Analysis
Given the need to account for confounding and selection bias in this retrospective investigation, individuals were matched with and without plasma transfusions using 1:1 propensity score matching based on INR, platelet count, aspirin, clopidogrel, warfarin, therapeutic unfractionated heparin, low-molecular-weight heparin, and direct thrombin inhibitor therapy. To account for missing platelet count values (7.1% missing), predicted probabilities of qualifying plasma transfusion were constructed employing random forest with 400 trees and imputation of missing values using the rfsrc function in the randomForestSRC R package (R Core Team, 2016). 25 These predicted probabilities were then used to propensity score match subjects 1:1 using the Matching v4.8-3.4 R package 26 with a caliper of 0.25. Imbalance in covariates was quantified using the percent of absolute difference ( Figure 2) and P values from the test assessing imbalance; Kolmogorov-Smirnov test for continuous covariates and Fisher exact test for categorical data. Differences >10% were considered to show residual imbalance. Although sex and race showed imbalance, there was no evidence of a clinical effect of these factors on outcome, so no further action was taken. Therapeutic heparin and INR were also found to be imbalanced and were subsequently used as covariates.
The binary end points of qualifying RBC transfusion (primary outcome) and 30-day mortality (secondary outcome) were modeled using logistic regression adjusting for confounding variables through propensity matching as described above, whereas secondary outcomes ICU-and hospital-free days were modeled using negative binomial generalized linear models. The effect of plasma transfusion was tested using a likelihood ratio test. An analysis of the matched pairs was conducted adjusting for therapeutic heparin and INR whereas an analysis of the entire cohort was unadjusted. To further assess the robustness of study findings, multiple sensitivity analyses were planned a priori including restriction to (1) medical ICU patients, (2) surgical ICU patients, and (3) patients with INR ≥ 1.5. To address the multiple tests conducted in Tables 2-4 , the P value threshold for significance of a single test was set at .003125 using a Bonferroni correction (ie, 0.05 ÷ 16 tests), to ensure a study-wise cutoff of .05. All analyses were performed using R v3.1.1.
The sample size was estimated at 2038 total study participants (2-sided α of .05, β = .20) by assuming an RBC transfusion rate of 10% in ICU patients with INR ≥ 1.5 (estimated to be 10% of the total ICU population based on historical data) and a plasma transfusion rate of 20% in this population to identify an odds ratio of 0.5 for RBC transfusion in those who receive prophylactic plasma compared with those who do not. This number was increased by 50% to facilitate a priori sensitivity analyses. To achieve this number of patients with elevated INRs, we conservatively estimated the need to evaluate 31,000 ICU admissions.
RESULTS
A total of 45,785 patients were admitted to an eligible ICU during the study period with 27,561 (60.2%) meeting inclusion criteria ( Figure 1 ). Of the 25,089 patients not receiving plasma therapy, 3009 were excluded having received an RBC transfusion in the 24 hours preceding INR www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA Prophylactic Plasma in the Critically Ill measurement. Of the 2472 patients receiving plasma, 1367 patients were excluded for having received RBC transfusion in the 24 hours preceding INR measurement or in the period between INR measurement and plasma transfusion. In total, 1105 patients received a prophylactic plasma transfusion (44.7% of plasma-transfused subjects) with a median (interquartile range) volume of 2 (1-2) units. The median time between INR measurement and plasma transfusion was 2.6 (1.2-4.9) hours.
Comparison of baseline clinical, demographic, and laboratory characteristics between plasma-transfused and nonplasma-transfused subjects are shown in Table 1 . Briefly, patients receiving plasma were older with a higher burden of comorbid disease and coagulation abnormalities and were more likely to be receiving warfarin anticoagulation. After propensity matching, between group differences were significantly reduced (Table 1, Figure 2 ).
A total of 2588 patients (9.3%) received a qualifying RBC transfusion in the 24 hours following INR measurement or plasma transfusion, including 2170 patients (9.8%) in the nonplasma group and 367 (33.2%) in the plasma-transfused group (P < .001). The median time to RBC transfusion from INR measurement was 5.4 (2.2-12.3) hours for the non-plasma-transfused group and 6.5 (3.8-12. 3) hours for the plasma-transfused group, with a median time from plasma to RBC transfusion of 3.6 (1.9-7.4) hours. Results of univariate analyses in the nonmatched cohort are displayed in Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/AA/B574). Briefly, those receiving plasma had higher rates of RBC transfusion, increased mortality, and fewer hospital-free days. The median RBC transfusion volume was statistically greater in those who received plasma than in those who did not (2 [2-2] units versus 2 [1-2] units, P = .003).
In total, 978 patients receiving prophylactic plasma were propensity matched 1:1 with a patient not receiving plasma. Of note, 127 patients receiving plasma were removed from propensity-matched analyses because of the lack of a suitable nontransfused subject. Propensity matching significantly reduced between group differences (Table 1, Figure   2 ); however, certain variables remained with absolute standardized differences greater than 10%, including INR with a median (interquartile range) of 1.6 (1.2-2.2) in the plasmatransfused group and 1.8 (1.5-2.4) in the non-plasmatransfused group and therapeutic heparin rates of 6.1% in the plasma-transfused group and 2.5% in the non-plasmatransfused group. Given these differences, all subsequent outcome modeling in the propensity-matched cohort contained adjustments for INR and heparin use.
The results of adjusted multivariable propensitymatched analyses for the full matched cohort are displayed in Table 2 . Patients receiving plasma had higher RBC transfusion rates (odds ratio 4.3 [95% confidence interval: 3.3-5.7], P < .001) and fewer hospital-free days (estimated decrease 11.0% [95% confidence interval: 10.6%-11.4%], P < .001) when compared with nonplasma-transfused subjects. There were no significant differences in mortality or ICUfree days.
Regarding the subgroup of patients with abnormal coagulation test results, 5038 patients (18.3%) had a qualifying INR value ≥ 1.5, of which 787 (15.6%) received prophylactic plasma. In total, 618 patients with INR ≥ 1.5 who were transfused plasma were propensity matched 1:1 with a nontransfused counterpart. When restricting analyses to these patients, plasma administration was associated with increased RBC transfusion rates and fewer hospital-free days, but no significant difference in mortality (Table 3) . Results of propensity-matched sensitivity analyses restricting the analysis to medical or surgical ICU patients are displayed in Table 4 . Briefly, plasma administration was associated with increased RBC requirements and fewer hospital-free days in both subpopulations. There was no significant difference in mortality in either group.
DISCUSSION
Plasma transfusion for the prevention of bleeding complications is common in the critically ill despite a lack of supporting evidence. In this investigation, prophylactic plasma transfusion was not associated with decreased RBC requirements. To the contrary, patients receiving plasma Estimates and P values are from logistic regression for categorical outcomes and negative binomial regression for length of stay. Model was adjusted using INR and therapeutic heparin. Odds ratios >1 imply increased odds for the outcome in those receiving plasma. Estimated % increase < 0 imply fewer free days in those receiving plasma. Numbers are n (%) for categorical outcomes and median (Q1, Q3) for continuous outcomes. Estimates and P values are from logistic regression for categorical outcomes and negative binomial regression for length of stay. Model was adjusted using INR and therapeutic heparin. Odds ratios > 1 imply increased odds for the outcome in those receiving plasma. Estimated % increase < 0 imply fewer free days in those receiving plasma. Estimates and P values are from logistic regression for categorical outcomes and negative binomial regression for length of stay. Model was adjusted using INR and therapeutic heparin. Odds ratios > 1 imply increased odds for the outcome in those receiving plasma. Estimated % increase < 0 imply fewer free days in those receiving plasma.
had higher rates of RBC transfusion in the subsequent 24 hours, a relationship that persisted in multiple predefined sensitivity analyses including limitation to those in either the medical or surgical ICU. In addition, patients transfused with plasma had fewer hospital-free days. Approximately 4 million units of plasma are transfused each year in the United States, with the majority of transfusions occurring outside published guidelines. 4, 27 In fact, there are few evidence-based indications for plasma transfusion. These include replacement of single coagulation factor or protein deficiencies for which no safe fractionated product exists, 28, 29 replacement of multiple factor deficiencies associated with severe bleeding and/or disseminated intravascular coagulation, 28 prevention of dilutional coagulopathy in the setting of massive hemorrhage and/or major trauma, 30 plasma exchange in thrombotic thrombocytopenic purpura, 28 and reversal of warfarin anticoagulation when severe bleeding is present and prothrombin complex concentrates are not available. 28 In contrast, there is a paucity of evidence regarding the prophylactic use of plasma for the prevention of bleeding complications in critically ill patients. Dara et al 1 retrospectively analyzed the effects of plasma transfusion in 115 patients with nonbleeding coagulopathy, finding no difference in bleeding episodes in transfused versus nontransfused patients. More recently, Müller et al 2 designed a randomized controlled trial of plasma transfusion in critically ill patients before invasive procedures, but this study was stopped before obtaining predefined target enrollment because of slow inclusion. In the 81 randomly assigned patients, the incidence of bleeding did not differ between transfused and nontransfused subjects, although the study was underpowered for the outcome measure. In addition, plasma transfusion (12 mL/kg) successfully reduced INR to <1.5 in only half of transfused patients. Furthermore, evidence suggests that even when plasma is successful in decreasing mild-to-moderately elevated INR values, the overall effects on thrombin generation are limited and normalization of coagulation status does not occur. 10 Although the precise mechanisms underlying this observation remain incompletely defined, it should be noted that plasma also contains anticoagulant and fibrinolytic proteins, and in vivo changes in anticoagulant-procoagulant balance are not adequately reflected in the INR.
Interestingly, in the current investigation, patients transfused with plasma had higher RBC requirements than those not receiving plasma, even when limiting analyses to those with elevated INR. Although the retrospective design of this investigation precludes the determination of the precise mechanisms associating plasma with higher RBC requirements, there are several theoretical explanations. First, transfusion practices differ by provider, and it is possible that providers inclined to transfuse plasma prophylactically would also be more likely to transfuse RBCs. Hence, the relationship between plasma and RBC transfusion may be a reflection of provider-specific transfusion practices. Second, patients who received plasma may have been inherently different (eg, more acutely ill or at greater risk of bleeding) than those who did not receive plasma despite attempts to balance baseline risk in adjusted analyses. Third, plasma is a high-volume product that may result in significant hemodilution; in some patients, reducing hemoglobin values beyond RBC transfusion thresholds. In addition, plasmaassociated volume expansion may potentially increase intravascular pressures and have the paradoxical effect of disrupting newly formed hemostatic plugs, analogous to the presumed benefit of maintaining permissive hypotension in major trauma 31 or utilizing restrictive transfusion strategies in acute gastrointestinal hemorrhage. 32 Finally, plasma may induce a change in the hemostatic balance of anticoagulant and procoagulant proteins, and there is evidence to suggest that, similarly to nonbleeding patients with liver disease 33, 34 and severe sepsis, 35 nonbleeding critically ill patients with mild-to-moderate elevations in INR may maintain normal in vivo hemostatic balance. 10 Although the large sample size, validated electronic data extraction techniques, and rigorous statistical adjustments are strengths of this investigation, there are significant limitations that must be mentioned. First, the retrospective nature of this study introduces the potential for confounding and bias despite attempts to mitigate these effects in the study design and analytical approach. We do note that propensity-matched analyses largely mitigated baseline differences in measured variables. In addition, residual imbalances in a small number of variables were further addressed in adjusted analyses. Nonetheless, the potential for unmeasured confounding persists and cannot be understated. Hence, the non-plasma-transfused group may have been sicker despite propensity matching, and this may have been reflected by increased rates of RBC transfusion. It should also be emphasized that the clinical motivation influencing transfusion decisions could not be standardized because this can only be accomplished with prospective investigation. Hence, this retrospective study can only identify associations between plasma transfusion and bleeding complications. The assessment of cause-effect relationships will require a robust clinical trial design. Second, it is possible that not all plasma transfusions were prophylactic in nature, because nonbleeding ICU patients may be transfused for other reasons including plasma exchange and the correction of antithrombin deficiency. In attempt to reduce this potential bias, we limited our analyses to a restricted population with abnormal INR values, assuming that abnormal results would be rare in the aforementioned clinical circumstances. The results of these sensitivity analyses were similar to the primary analyses. In addition, the exclusion of patients receiving RBCs in the 24 hours before INR measurement or plasma transfusion may have inadvertently removed some nonbleeding patients from further analysis; however, this exclusion was predefined to minimize the risk of including therapeutic plasma transfusion episodes occurring in the setting of resuscitation from active hemorrhage. It would have been possible to extend this time period of exclusion to patients receiving RBCs in the 48 or 72 hours before INR measurement or plasma transfusion, potentially excluding additional patients that had recently suffered hemorrhage. However, because RBC transfusion is common in the ICU and is often triggered by anemia without signs of active bleeding, this would also have resulted in a greater likelihood of inappropriate exclusion of nonbleeding patients. In addition, it is unlikely that a patient with no RBC transfusion requirements over a 24-hour interval has continued to experience significant active bleeding. Another limitation of this investigation is the relatively low dose of plasma utilized with a median volume of 2 units, which corresponds to approximately 7 mL/kg for the average adult patient. Previous studies have consistently noted that plasma volumes <10 mL/kg are unlikely to correct an abnormal INR; hence, the lack of perceived benefit may have been attributable, in part, to inadequate plasma dosing. Finally, this study reflects the experience of a single academic medical center and will require validation to ensure external validity and generalizability.
In conclusion, prophylactic administration of plasma was not associated with reduced bleeding complications or improved outcomes in a large population of critically ill patients. In light of these findings, more conservative management of coagulation abnormalities in nonbleeding ICU patients may be warranted, although further research is necessary to better understand the relationship between prophylactic plasma and subsequent RBC transfusion episodes. E
